Seebri Breezhaler - Glycopyrronium

Novartis Consumer Health

Description

Antimuscarinic bronchodilator.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.

Indications

For the maintenance treatment of COPD.

Contraindications

Avoid in the case of renal impairment, pregnancy or breast feeding.

Preparations Available

Inhalation powder

Sizes Available

Seebri Breezhaler, 55 mcg inhalation powder capsules, 10 capsules
Seebri Breezhaler, 55 mcg inhalation powder capsules, 30 capsules

More on: Bronchodilators , Antimuscarinic bronchodilators